What is PhoreMost?
Founded in 2014, PhoreMost operates at the intersection of high-throughput biology and computational drug discovery. The company's core technology, the SITES platform, enables the systematic identification of novel druggable sites across the entire human proteome. By moving beyond traditional target-based approaches, PhoreMost provides a robust framework for identifying therapeutic candidates that were previously considered inaccessible. This phenotypic screening capability is essential for modern pharmaceutical research, allowing for the rapid validation of targets in complex disease models. As a leader in the UK biotech ecosystem, PhoreMost maintains a strategic focus on translating academic innovation into scalable commercial solutions, effectively bridging the gap between fundamental research and clinical application.
How much funding has PhoreMost raised?
PhoreMost has raised a total of $68.8M across 3 funding rounds:
Angel/Seed
$3.8M
Series A
$15M
Series B
$50M
Angel/Seed (2015): $3.8M with participation from Cambridge Enterprise
Series A (2018): $15M, investors not publicly disclosed
Series B (2024): $50M supported by Jonathan Milner, Parkwalk Advisors, XtalPi, The Morningside Group, BGF, o2h ventures, Trend Investments Group, and Astellas Venture Management
Key Investors in PhoreMost
Parkwalk Advisors
Parkwalk is a leading investor in university spinouts, focusing on deeptech innovations emerging from the UK's top universities. They bridge the gap between academic research and commercial success by providing funding, expertise, and networks to help these companies thrive.
BGF
BGF is the most active and influential investor in small and mid-sized businesses in the UK. An established and independent company, it supports a range of growing companies across every region and sector of the economy.
Astellas Venture Management
Astellas Venture Management is the corporate venture capital arm of Astellas Pharma, a global pharmaceutical company engaged in the manufacturing, marketing, and development of innovative medicines.
What's next for PhoreMost?
With the successful closure of this major enterprise-level funding, PhoreMost is well-positioned to accelerate its internal pipeline and expand its strategic partnerships. The capital will likely be deployed to scale the SITES platform's throughput and enhance its computational capabilities, further solidifying the company's competitive advantage in the drug discovery sector. Future growth will likely center on deepening collaborations with global pharmaceutical entities and advancing lead programs into preclinical development. As the company transitions into this next phase of maturity, the focus will remain on maintaining its technological edge while navigating the complexities of the global biopharmaceutical market, ensuring that its phenotypic screening innovations continue to address critical unmet medical needs.
See full PhoreMost company page
